WO2017169873A1 - 共重合体、湿潤剤、医療デバイスおよびその製造方法 - Google Patents
共重合体、湿潤剤、医療デバイスおよびその製造方法 Download PDFInfo
- Publication number
- WO2017169873A1 WO2017169873A1 PCT/JP2017/010824 JP2017010824W WO2017169873A1 WO 2017169873 A1 WO2017169873 A1 WO 2017169873A1 JP 2017010824 W JP2017010824 W JP 2017010824W WO 2017169873 A1 WO2017169873 A1 WO 2017169873A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- meth
- group
- monomer
- medical device
- acrylamide
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/10—Esters
- C08F220/34—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate
- C08F220/36—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate containing oxygen in addition to the carboxy oxygen, e.g. 2-N-morpholinoethyl (meth)acrylate or 2-isocyanatoethyl (meth)acrylate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/14—Organic compounds not covered by groups A61L12/10 or A61L12/12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/085—Macromolecular materials
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/52—Amides or imides
- C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/52—Amides or imides
- C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
- C08F220/56—Acrylamide; Methacrylamide
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D133/00—Coating compositions based on homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Coating compositions based on derivatives of such polymers
- C09D133/24—Homopolymers or copolymers of amides or imides
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
- G02B1/04—Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
- G02B1/041—Lenses
- G02B1/043—Contact lenses
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C7/00—Optical parts
- G02C7/02—Lenses; Lens systems ; Methods of designing lenses
- G02C7/04—Contact lenses for the eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/10—Materials for lubricating medical devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/10—Esters
- C08F220/26—Esters containing oxygen in addition to the carboxy oxygen
- C08F220/28—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety
- C08F220/283—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety and containing one or more carboxylic moiety in the chain, e.g. acetoacetoxyethyl(meth)acrylate
Definitions
- the present invention relates to a specific copolymer, a medical device having the copolymer on a surface, and a wetting agent including the copolymer.
- the wetting agent containing the copolymer is suitable as an external wetting agent for ophthalmic lenses, particularly contact lenses.
- a medical device that comes into direct contact with a part of the human body needs to have biocompatibility on its surface.
- biocompatibility it is important that the adhesion of substances such as water, protein and lipid is controlled.
- a soft water contact lens with a high water content is made by a water-containing gel (hydrogel) formed by polymerizing a hydrophilic monomer such as 2-hydroxyethyl methacrylate (HEMA) in the presence of a small amount of a crosslinking agent.
- a hydrophilic monomer such as 2-hydroxyethyl methacrylate (HEMA)
- HEMA 2-hydroxyethyl methacrylate
- low-hydrous or non-hydrous soft contact lenses often use hydrophobic monomers, so they are not slippery or even have poor water wettability. Is required.
- Patent Document 1 polyvinyl pyrrolidone (PVP), which is a hydrophilic polymer, is added to a packaging solution enclosed in a blister pack, and contact lenses are immersed and steam sterilized, so that the surface of a highly hydrous lens can be easily obtained.
- PVP polyvinyl pyrrolidone
- Patent Document 2 a contact lens is immersed in a packaging solution containing acid-terminated PVP generated by reaction of hydroxyl-functionalized poly (vinyl pyrrolidone) or poly (vinyl pyrrolidone-co-allyl alcohol) with succinic anhydride, and steam A method for imparting slipperiness to the surface of a silicone hydrogel lens by sterilization is disclosed.
- Patent Document 3 examples include n-butyl acrylate, styrene, acrylic amide, acrylic acid ester of N- ⁇ -hydroxyethylpyrrolidone and sodium salt of maleic acid mono- ⁇ -methoxyethyl ester. Compounds obtained by copolymerizing the components are described. However, the compound is used in an aqueous dispersion, is suspended in a liquid, and is not soluble in water. Moreover, the said literature does not have description about using the said compound for a medical use.
- a polymer for surface treatment in which a medical device such as a contact lens suppresses a decrease in slipperiness even by rubbing by surface treatment by an approach different from the above-described conventional technology
- the present invention has the following configuration. That is,
- Monomer A a (meth) acryloyl group and an ester structure or an amide structure in the molecule, and the ester structure and the amide structure are not configured to include a part of the (meth) acryloyl group
- Monomer Monomer B A monomer having a (meth) acrylamide group in the molecule and having a structure different from that of the monomer A2.
- a medical device comprising a substrate and the copolymer of the present invention in at least a part on the surface of the substrate. 3.
- a wetting agent comprising the copolymer of the present invention. 4).
- a method of wetting a medical device comprising bringing the wetting agent of the present invention into contact with a medical device. 5.
- a method for producing a medical device comprising a step of placing the wetting agent of the present invention and the medical device substrate in a container and heat-treating the same.
- the copolymer according to the present invention can be provided as a wetting agent containing the copolymer because it can suppress a decrease in slipperiness of the surface of a medical device such as a contact lens over time. Moreover, the medical device which has the said copolymer on the surface suppresses the fall of slipperiness with time.
- the copolymer of the present invention comprises a monomer A having a (meth) acryloyl group and an ester structure or an amide structure in the molecule, and a monomer B having a (meth) acrylamide group in the molecule and a structure different from that of the monomer A. And the structural unit.
- the ester structure and the amide structure do not include a part of the (meth) acryloyl group.
- (Meth) acryloyl group in this specification represents both acryloyl group and methacryloyl group.
- (Meth) acrylamide group in this specification represents both acrylamide group and methacrylamide group.
- Monomer A is preferably a monomer in which a (meth) acryloyl group is bonded to an ester structure or an amide structure via a divalent hydrocarbon group having a hetero atom.
- the ester structure does not include a part of the (meth) acryloyl group, but is a structure that exists separately from the (meth) acryloyl group, and represents an acyloxy group, for example, an acetoxy group A linear or branched alkylcarbonyloxy group having 1 to 10 carbon atoms such as a propanoyloxy group, a butanoyloxy group, a 2-methylpropanoyloxy group, a pentanoyloxy group, or a 2,2-dimethylpropanoyloxy group; Cycloalkylcarbonyloxy group having 3 to 10 carbon atoms such as cyclopropylcarbonyloxy group, cyclopentylcarbonyloxy group, cyclohexylcarbonyloxy group, cycloheptylcarbonyloxy group; benzoyloxy group, 2-methylbenzoyloxy group, 3-methylbenzoyl Oxy group, 4-me Reuben benzoyl
- the amide structure does not include a part of the (meth) acryloyl group, but is a structure that exists separately in the monomer A, specifically, an acylamino group, an N-alkylacyl group.
- An amino group and a lactam group are preferable, and examples thereof include an acylamino group having 1 to 10 carbon atoms such as acetylamino group, propionylamino group, butyrylamino group, isobutyrylamino group, valerylamino group, isovalerylamino group, and pivaloylamino group; N -Substitution on a nitrogen atom with an alkyl group having 1 to 6 carbon atoms such as methylacetylamino group, N-ethylacetylamino group, N-methylpropionylamino group, N-ethylpropionylamino group, and N-methylbutyrylamino group Said acylamino group;
- the heteroatom represents an oxygen atom, a nitrogen atom or a sulfur atom, preferably an oxygen atom or a nitrogen atom.
- the above divalent hydrocarbon group includes, for example, an alkylene group such as a methylene group, an ethylene group, a propylene group, a butylene group; a 1,2-cyclopropylene group, a 1,3-cyclopentylene group, Examples thereof include cycloalkylene groups such as 1,2-cyclohexylene group and 1,4-cyclohexylene group; arylene groups such as phenylene group and naphthylene group.
- examples of the divalent hydrocarbon group having a hetero atom include an oxymethylene group (—CH 2 O—), an oxyethylene group (—CH 2 CH 2 O—), and an oxypropylene group (—CH 2 CH 2).
- Oxyalkylene groups such as CH 2 O—) and oxybutylene groups (—CH 2 CH 2 CH 2 O—); aminomethylene groups (—CH 2 NH—), aminoethylene groups (—CH 2 CH 2 NH—) ), An aminopropylene group (—CH 2 CH 2 CH 2 NH—), an aminobutylene group (—CH 2 CH 2 CH 2 NH—) or the like; an N-methylaminomethylene group (—CH 2 NCH) 3 -), N-methylamino ethylene group (-CH 2 CH 2 NCH 3 - ), N- methylamino propylene group (-CH 2 CH 2 CH 2 NC 3 -), N-methylamino-butylene group (-CH 2 CH 2 CH 2 CH 2 NCH 3 -) N- alkylamino alkylene group and the like; oxyphenylene group, oxyarylene groups such Okishinafuchiren group; amino phenylene group, amino Examples thereof include aminoarylene groups such as naphthylene group
- Monomer A includes a compound having a structure represented by the following formula [I].
- R 1 represents a hydrogen atom or a methyl group.
- R 2 represents an alkyl group.
- X represents an oxygen atom or NR 3
- R 3 represents a hydrogen atom or an alkyl group.
- Y represents an oxygen atom or NR 4
- R 4 represents a hydrogen atom or an alkyl group, and R 4 may combine with R 2 to form a ring structure.
- m represents an integer of 1 to 4.
- a more preferable structure as the monomer A is a compound represented by the following formula [II].
- R 1 represents a hydrogen atom or a methyl group.
- X represents an oxygen atom or NR 3
- R 3 represents a hydrogen atom or an alkyl group.
- m represents an integer of 1 to 4.
- n represents an integer of 1 to 3.
- R 2 may be linear or branched and is preferably an alkyl group having 1 to 10 carbon atoms, such as a methyl group, an ethyl group, a propyl group, a 2-propyl group, a butyl group, or a 2-butyl group. Tert-butyl group, pentyl group, 2-pentyl group, 3-pentyl group, hexyl group, heptyl group, octyl group and the like.
- R 3 is an alkyl group, it may be linear or branched and is preferably an alkyl group having 1 to 6 carbon atoms, such as a methyl group, an ethyl group, a propyl group, a 2-propyl group, a butyl group, Examples include 2-butyl group, tert-butyl group, pentyl group, 2-pentyl group, 3-pentyl group, hexyl group and the like.
- R 4 is an alkyl group, it may be linear or branched and is preferably an alkyl group having 1 to 6 carbon atoms, such as a methyl group, an ethyl group, a propyl group, a 2-propyl group, a butyl group, Examples include 2-butyl group, tert-butyl group, pentyl group, 2-pentyl group, 3-pentyl group, hexyl group and the like.
- R 4 When R 4 is bonded to R 2 to form a ring structure, R 4 may be linear or branched and is preferably an alkylene group having 2 to 6 carbon atoms, such as ethylene group, propylene Group, butylene group, pentylene group and the like.
- Suitable monomer A include 2-acetoxyethyl (meth) acrylate, 2- (propionyloxy) ethyl (meth) acrylate, 2- (butyryloxy) ethyl (meth) acrylate, 2- (isobutyryloxy) Ethyl (meth) acrylate, 2- (3-methylbutyryloxy) ethyl (meth) acrylate, 2- (pivaloyloxy) ethyl (meth) acrylate, 3-acetoxypropyl (meth) acrylate, 3- (propionyloxy) propyl ( (Meth) acrylate, 3- (butyryloxy) propyl (meth) acrylate, 3- (isobutyryloxy) propyl (meth) acrylate, 3- (3-methylbutyryloxy) propyl (meth) acrylate, 3- (pivaloyloxy) Propyl (meth) acrylate, 4-acetoxybutyl (meth)
- Y in the formula [I] is a nitrogen atom monomer A as 2-acetamidoethyl (meth) acrylate, 2-propionamidoethyl (meth) acrylate, 2-butylamidoethyl.
- m in formula [I] is more preferably 2 or less from the viewpoint of high hydrophilicity, 2-acetamidoethyl (meth) acrylate, 2-propionamidoethyl (meth) acrylate, 2-butylamide Ethyl (meth) acrylate, 2-isobutylamidoethyl (meth) acrylate, 2- (3-methylbutanamido) ethyl (meth) acrylate, 2-pivalamidoethyl (meth) acrylate, 2- (2-oxopyrrolidine- 1-yl) ethyl (meth) acrylate, 2- (2-oxopiperidin-1-yl) ethyl (meth) acrylate, 2- (2-oxoazepan-1-yl) ethyl (meth) acrylate, N- (2- Acetamidoethyl) (meth) acrylamide, N- (2-propionamidoe
- n in the formula [II] is most preferably 1, and 2- (2-oxopyrrolidin-1-yl) ethyl (meth) acrylate, N- (2- ( 2-oxopyrrolidin-1-yl) ethyl) (meth) acrylamide.
- Monomer A can be used alone or in combination of two or more.
- Monomer B is a monomer having a (meth) acrylamide group in the molecule and having a structure different from that of monomer A, preferably having hydrophilicity, and a particularly preferred structure is represented by the following formula [III]: It is a compound represented.
- R 5 represents a hydrogen atom or a methyl group.
- R 6 and R 7 each independently represents a hydrogen atom or an alkyl group, and R 6 and R 7 may combine to form a ring structure.
- R 6 and R 7 are preferably an alkyl group.
- each of R 6 and / or R 7 is an alkyl group, it may be linear or branched and is preferably an alkyl group having 1 to 6 carbon atoms, such as a methyl group, an ethyl group, a propyl group, 2- Examples include propyl group, butyl group, 2-butyl group, tert-butyl group, pentyl group, 2-pentyl group, 3-pentyl group, hexyl group and the like.
- R 6 -R 7 where R 6 and R 7 are bonded may be linear or branched, and is an alkylene group having 2 to 6 carbon atoms
- alkylene group having 2 to 6 carbon atoms For example, ethylene group, 1,2-propylene group, 1,3-propylene group, 1,2-butylene group, 1,3-butylene group, 1,4-butylene group, 1,5- A pentylene group is exemplified.
- the monomer being hydrophilic means that the solubility in water or a borate buffer solution at 25 ° C. is 0.1% by mass or more, and is 1.0% by mass or more. More preferably, it is more preferably 10% by mass or more.
- the borate buffer used in the present invention is 8.48 g of sodium chloride, 9.26 g of boric acid, 1.0 g of sodium borate (sodium tetraborate decahydrate) and 0.10 g of ethylenediaminetetraacetic acid. It is an aqueous solution made up to 1 L by dissolving in pure water, and different amounts of aqueous solution may be used as long as the mixing ratio is the same.
- suitable monomer B include N-methyl (meth) acrylamide, N-ethyl (meth) acrylamide, N-propyl (meth) acrylamide, N-butyl (meth) acrylamide, N, N-dimethyl (meth) Acrylamide, N-ethyl-N-methyl (meth) acrylamide, N-methyl-N-propyl (meth) acrylamide, N-butyl-N-methyl (meth) acrylamide, N, N-diethyl (meth) acrylamide, N- Examples thereof include ethyl-N-propyl (meth) acrylamide, N-butyl-N-ethyl (meth) acrylamide, 1- (meth) acryloylpyrrolidine, 1- (meth) acryloylpiperidine and the like.
- R 6 and / or R 7 preferably have 3 or less carbon atoms from the viewpoint of a more hydrophilic monomer, and among these, N-methyl (meth) acrylamide, N-ethyl (meta) ) Acrylamide, N-propyl (meth) acrylamide, N, N-dimethyl (meth) acrylamide, N-ethyl-N-methyl (meth) acrylamide, N-methyl-N-propyl (meth) acrylamide, N, N-diethyl Examples include (meth) acrylamide, N-ethyl-N-propyl (meth) acrylamide, and 1- (meth) acryloylpiperidine.
- the total number of carbon atoms of R 6 and R 7 is preferably 2 or less, and N-methyl (meth) acrylamide, N-ethyl (meth) acrylamide, and N, N-dimethyl (meth) acrylamide are most preferable.
- Monomer B can be used alone or in combination of two or more.
- the copolymer in the present invention has the above-mentioned monomer A and the above-mentioned monomer B as structural units. These can be linear or branched, random copolymers, alternating copolymers, block copolymers, and graft copolymers, but are not particularly limited.
- the copolymer in the present invention is preferably water-soluble.
- Water-soluble means that the solubility of the copolymer in water or borate buffer solution at 25 ° C. is 0.1% by mass or more, more preferably 1.0% by mass or more. More preferably, it is at least mass%. Although the upper limit of solubility is not specifically limited, Usually, solubility is 50 mass% or less.
- an aqueous solution in which such a water-soluble copolymer is dissolved forms a transparent solution, not an emulsion (dispersion).
- the copolymer is not soluble in water, it is not preferable because the surface of the medical device may not be coated evenly as a wetting agent.
- the copolymer of the present invention may be dissolved in water to form an aqueous solution, or may be added to an aqueous solution previously prepared.
- aqueous solution before dissolving the copolymer include, but are not limited to, salt water, other buffer solutions, and deionized water.
- a preferred aqueous solution is a saline solution containing a salt, such as sodium chloride, sodium borate, sodium phosphate, sodium hydrogen phosphate, sodium dihydrogen phosphate, or the corresponding potassium salt of the acid. However, it is not limited to these. These components generally mix to form a buffer containing the acid and its conjugate base, so that the addition of acid or base causes only a relatively small change in pH.
- the buffer further comprises 2- (N-morpholino) ethanesulfonic acid (MES), sodium hydroxide, 2,2-bis (hydroxymethyl) -2,2 ′, 2 ′′ -nitrilotriethanol, N-tris (hydroxy Methyl) methyl-2-aminoethanesulfonic acid, citric acid, sodium citrate, sodium carbonate, sodium bicarbonate, acetic acid, sodium acetate, ethylenediaminetetraacetic acid, and the like, and combinations thereof may further be included.
- the solution is a borate buffered saline solution (same as the borate buffer solution described above) or a phosphate buffered saline solution.
- the content of monomer A and monomer B in the copolymer in the present invention is not particularly limited, but the content of monomer A is 5 to 50 mol%, and the content of monomer B is 50 to 95. It is preferable that it is mol%.
- the content of monomer A is more preferably 5 to 35 mol%, and the content of monomer B is more preferably 65 to 95 mol%. Any combination of the above upper and lower limits may be used.
- the copolymer of the present invention can be produced by polymerizing the monomer A and the monomer B described above.
- a polymerization initiator may be added to accelerate the polymerization.
- Suitable initiators include thermal polymerization initiators such as peroxides and azo compounds, photopolymerization initiators (which may be ultraviolet light, visible light, or a combination), or mixtures thereof.
- thermal polymerization initiators such as peroxides and azo compounds
- photopolymerization initiators which may be ultraviolet light, visible light, or a combination
- thermal polymerization initiator having an optimum decomposition characteristic for a desired reaction temperature is selected and used.
- an azo initiator or a peroxide initiator having a 10 hour half-life temperature of 40 ° C. to 120 ° C. is preferable.
- the photopolymerization initiator include carbonyl compounds, peroxides, azo compounds, sulfur compounds, halogen compounds, metal salts and the like.
- thermal polymerization initiator examples include 2,2′-azobis (isobutyronitrile) (AIBN), 2,2′-azobis (2-methylbutyronitrile), 2,2′-azobis (2, 4-dimethylvaleronitrile), 1,1′-azobis (cyclohexane-1-carbonitrile), 2,2′-azobis [2- (2-imidazolin-2-yl) propane], 2,2′-azobis ( 2-amidinopropane) dihydrochloride, 2,2′-azobis [N- (2-carboxyethyl) -2-methylpropionamidine], 2,2′-azobis [2-methyl-N- (2-hydroxyethyl) ) Propionamide], 2,2′-azobis (N-butyl-2-methylpropionamide), 2,2′-azobis (2-methylpropionic acid) dimethyl, 4,4′-azobis (4- Ano valerate), tert-butyl hydroperoxide, cumene hydroperoxide, di -tert-
- 2,2′-azobis isobutyronitrile
- 2,2′-azobis ( 2,4-dimethylvaleronitrile) 1,1′-azobis (cyclohexane-1-carbonitrile)
- 2,2′- Azobis [2-methyl-N- (2-hydroxyethyl) propionamide]
- 2,2′-azobis N-butyl-2-methylpropionamide
- tert-butyl hydroperoxide cumene hydroperoxide, di-tert-butyl peroxide, benzoyl peroxide are preferred. It is needed.
- photopolymerization initiator examples include aromatic ⁇ -hydroxyketone, alkoxyoxybenzoin, acetophenone, acylphosphine oxide, bisacylphosphine oxide, tertiary amine + diketone, and mixtures thereof. More specific examples include 1-hydroxycyclohexyl phenyl ketone, 2-hydroxy-2-methyl-1-phenyl-propan-1-one, bis (2,6-dimethoxybenzoyl) -2,4,4-trimethyl.
- Pentylphosphine oxide (DMBAPO), bis (2,4,6-trimethylbenzoyl) phenylphosphine oxide (“Irgacure” ® 819), 2,4,6-trimethylbenzyldiphenylphosphine oxide and 2,4,6- Examples include trimethylbenzoyldiphenylphosphine oxide, benzoin methyl ether, and a combination of camphorquinone and ethyl 4- (N, N-dimethylamino) benzoate.
- visible light initiators include “Irgacure” (registered trademark) 819, “Irgacure” (registered trademark) 1700, “Irgacure” (registered trademark) 1800, “Irgacure” (registered trademark) 1850 (above, manufactured by BASF). , And Lucillin TPO initiator (manufactured by BASF).
- Commercially available ultraviolet light initiators include “Darocur” (registered trademark) 1173 and “Darocur” (registered trademark) 2959 (manufactured by BASF).
- polymerization initiators may be used alone or in combination, and the amount used should be appropriately adjusted according to the target molecular weight of the copolymer to be obtained, but if it is too small, polymerization does not start, If the amount is too large, the molecular weight tends to be low, recombination is likely to stop, and it is difficult to obtain a polymer having a desired molecular weight. Therefore, the amount of the polymerization initiator used is 0.01 mass relative to the polymerization mixture. The range of from 5% to 5% by weight is preferred.
- the polymerization mixture refers to a reaction solution containing a monomer for polymerizing a polymer, and refers to a solution containing a monomer to be polymerized, a polymerization solvent and a polymerization initiator.
- This polymerization mixture may contain a chain transfer agent.
- Preferred examples of the chain transfer agent include mercaptans such as hydroxyethyl mercaptan, lauryl mercaptan, n-dodecyl mercaptan, ⁇ -methylstyrene dimer, limonene and the like.
- a polymerization solvent can be used.
- the solvent may be either an organic solvent or an inorganic solvent.
- solvents include: water; methanol, ethanol, propanol, 2-propanol, butanol, 2-butanol, tert-butyl alcohol, tert-amyl alcohol, 3,7-dimethyl-3-octanol, ethylene glycol, diethylene glycol, tri Alcohol solvents such as ethylene glycol, tetraethylene glycol and polyethylene glycol; aromatic hydrocarbon solvents such as benzene, toluene and xylene; aliphatic carbonization such as hexane, heptane, octane, decane, petroleum ether, kerosene, ligroin and paraffin Hydrogen solvents; cycloaliphatic hydrocarbon solvents such as cyclopentane, cyclohexane and ethyl
- ether solvents These solvents can be used alone or in combination. Of these, water, tert-butyl alcohol, tert-amyl alcohol, and 3,7-dimethyl-3-octanol are preferably used from the viewpoint that radical polymerization is difficult to inhibit.
- the monomer concentration in the polymerization mixture is preferably 10% by mass to 80% by mass because a sufficient molecular weight cannot be obtained if it is too low, and if it is too high, there is a risk of runaway due to the heat of polymerization. 15 mass% to 65 mass% is more preferable, and 20 mass% to 50 mass% is most preferable. The range which combined any of the said upper limit and the minimum may be sufficient.
- the copolymer obtained according to the method of the present invention is purified using conventional polymer isolation means such as distillation, column chromatography, precipitation, washing with a solvent insoluble in the copolymer, and fractionation by GPC. May be.
- the copolymer of the present invention has a mass average molecular weight that is too low, sufficient slipperiness may not be obtained. On the other hand, if the mass average molecular weight is too high, the viscosity of the solution containing the copolymer may become too high and the operability may be lost.
- the weight average molecular weight of the copolymer is preferably 5,000 to 5,000,000 daltons, more preferably 50,000 to 3,000,000 daltons, and 80,000 to More preferred is 1,000,000 daltons. The range which combined any of the said upper limit and the minimum may be sufficient.
- the copolymer in the present invention can be used for imparting slidability to plastic molded products such as medical devices and films, but can be particularly suitably used for medical devices.
- Medical devices include ophthalmic lenses, endoscopes, catheters, infusion tubes, gas transport tubes, stents, sheaths, cuffs, tube connectors, access ports, drainage bags, blood circuits, wound dressings, implants, and various drug carriers Among them, an ophthalmic lens is preferable.
- the ophthalmic lens include a contact lens such as a soft contact lens, a hard contact lens, and a hybrid contact lens, a scleral lens, an intraocular lens, an artificial cornea, a corneal inlay, a corneal onlay, and an eyeglass lens.
- the medical device is an ophthalmic lens
- it is preferably a contact lens, more preferably a soft contact lens, still more preferably a hydrogel soft contact lens, and particularly preferably a HEMA soft contact lens. is there.
- the medical device of the present invention has the above-mentioned copolymer having the above-mentioned monomer A and the above-mentioned monomer B as structural units on at least a part of the surface of the base material constituting the medical device.
- a base material constituting such a medical device (meth) acrylamides such as N, N-dimethylacrylamide, N-vinylamides such as N-vinylpyrrolidone, 2-hydroxyethyl (meth) acrylate, 2-methoxyethyl ( Hydroxyalkyl (meth) acrylates such as (meth) acrylate and alkyl ethers thereof, polyethylene glycol mono (meth) acrylates such as diethylene glycol mono (meth) acrylate, diethylene glycol mono (meth) acrylate methyl ether, and methyl ethers thereof Hydrophilic compounds and optionally di (meth) acrylates such as polyethylene glycol di (meth) acrylate, N, N-
- the copolymer in the present invention is formed on the surface of the substrate by at least one of a covalent bond, hydrogen bond, electrostatic interaction, hydrophobic interaction, chain entanglement, and van der Waals force. Present, and some may infiltrate the interior of the substrate. These interactions stabilize the copolymer in the vicinity of the substrate surface and improve the slidability of the medical device.
- the medical device is an ophthalmic lens, particularly a contact lens, it favors a comfortable wearing feeling.
- the surface of the medical device has excellent slipperiness.
- a smaller dynamic friction coefficient measured by the method shown in the examples of the present specification is preferable.
- the dynamic friction coefficient is preferably 0.2 or less.
- the dynamic friction coefficient is preferably 0.01 or more.
- the dynamic friction coefficient is measured with respect to the glass surface with a sample wet with borate buffer.
- the wettability of the device surface is determined by using a known contact angle measurement method (that is, a droplet method, a captive bubble method, or a dynamic contact angle measurement method). be able to.
- a known contact angle measurement method that is, a droplet method, a captive bubble method, or a dynamic contact angle measurement method.
- the contact angle hysteresis (DCA hysteresis) measured by the method shown in the examples described later in this specification is smaller.
- the DCA hysteresis is preferably 8 ° or less, more preferably 6 ° or less, and particularly preferably 5 ° or less.
- the lower limit may be 0 °, but it may be difficult in practice, and 0.5 ° is good. The range which combined any of the said upper limit and the minimum may be sufficient.
- the wetting agent of the present invention contains the copolymer of the present invention, and can bind to and / or infiltrate the surface of the base material due to the aforementioned interaction.
- the wetting agent is a surfactant that increases the action of making the surface of a solid easy to wet, and is preferably a polymer that imparts slipperiness to the surface of a medical device.
- the polymer provided is more preferred.
- the external wetting agent is a kind of wetting agent, and refers to a wetting agent for coating the surface of the medical device, for example, by physically contacting the surface of the medical device.
- the wetting agent may be in the form of any aqueous solution used for storage of medical devices.
- the aqueous medium include, but are not limited to, salt water, other buffer solutions, and deionized water.
- a preferred aqueous solution is a saline solution containing a salt, such as sodium chloride, sodium borate, sodium phosphate, sodium hydrogen phosphate, sodium dihydrogen phosphate, or the corresponding potassium salt of the same acid.
- a salt such as sodium chloride, sodium borate, sodium phosphate, sodium hydrogen phosphate, sodium dihydrogen phosphate, or the corresponding potassium salt of the same acid.
- sodium chloride sodium borate
- sodium phosphate sodium hydrogen phosphate
- sodium dihydrogen phosphate sodium dihydrogen phosphate
- potassium salt such as sodium chloride, sodium borate, sodium phosphate, sodium hydrogen phosphate, sodium dihydrogen phosphate, or the corresponding potassium salt of the same acid.
- These components generally mix to form a buffer containing the
- the buffer further comprises 2- (N-morpholino) ethanesulfonic acid (MES), sodium hydroxide, 2,2-bis (hydroxymethyl) -2,2 ′, 2 ′′ -nitrilotriethanol, N-tris (hydroxy Methyl) methyl-2-aminoethanesulfonic acid, citric acid, sodium citrate, sodium carbonate, sodium bicarbonate, acetic acid, sodium acetate, ethylenediaminetetraacetic acid, and the like, and combinations thereof may further be included.
- the solution is a borate buffered saline solution or a phosphate buffered saline solution.
- the solution also contains known additional ingredients such as viscosity modifiers, antibacterial agents, polyelectrolytes, stabilizers, chelating agents, antioxidants, and combinations thereof in concentrations that do not adversely affect the effectiveness of the present invention. May be.
- the surface of the medical device can be coated by physically contacting the surface of the medical device with the wetting agent containing the copolymer of the present invention, and thereby the medical device can be wetted. That is, the surface of a medical device such as an ophthalmic lens can be coated by placing a wetting agent and a medical device substrate in a container and heat-treating the container.
- suitable heat treatment may include heating for 10 to 60 minutes in a temperature range of 40 ° C. to 150 ° C., particularly preferably at a temperature of about 120 ° C. Examples include, but are not limited to, a conventional heat sterilization cycle that takes about 30 minutes, and may be performed in an autoclave. If heat sterilization is not used, the packaged lenses may be individually heat treated. Suitable temperatures for the individual heat treatment include at least about 40 ° C. or higher, preferably about 80 ° C. or higher. Suitable heat treatment times include at least about 10 minutes, with 10 minutes to 1 hour being preferred. Higher temperatures can require less processing time.
- ⁇ Analysis method and evaluation method> (1) Molecular weight measurement of polymer It measured using Shimadzu Corporation Prominence GPC system.
- the device configuration is as follows. Pump: LC-20AD, autosampler: SIL-20AHT, column oven: CTO-20A, detector: RID-10A, column: GMPWXL manufactured by Tosoh Corporation (inner diameter 7.8 mm ⁇ 30 cm, particle diameter 13 ⁇ m).
- the sample concentration was 0.2% by mass, and the sample injection amount was 20 ⁇ L.
- the calibration curve was calculated using a PEG / PEO standard sample (0.1 kD to 1258 kD) manufactured by Agilent.
- the sample subjected to the above evaluation is placed in a dent in the center of the palm, and a cleaning solution (“Optifree” (registered trademark), manufactured by Nippon Alcon Co., Ltd.) is added. After rubbing each time, it was washed thoroughly with water. The above operation was set as one cycle and repeated 14 cycles. Thereafter, the sample was washed with pure water and immersed in a phosphate buffer.
- the sensitivity evaluation of the 1st to 14th cycles was performed by the following five-level evaluation.
- FIG. 1 shows the evaluation results in 14 cycles.
- NMR measurement was performed using a JNM-EX270 nuclear magnetic resonance apparatus manufactured by JEOL. 1 H-NMR was measured using a solution in which about 5 mg of the measurement target compound was dissolved in about 0.6 mL of deuterated solvent (deuterated chloroform) as a measurement sample.
- VPA copolymer obtained in Reference Example 1
- DMA manufactured by Wako Pure Chemical, 3.56 g, 35.9 mmol
- ADVN 2,2′-azobis (2,4-dimethylvaleronitrile)
- TAA Tokyo Chemical Industry, 11.
- TAA 20,15 g, manufactured by Tokyo Chemical Industry Co., Ltd.
- a Dimroth condenser equipped with a dropping funnel, a digital thermometer and a three-way cock, stirring blade With a sealer attached.
- nitrogen was bubbled for 10 minutes to remove dissolved oxygen in the solvent.
- the reaction vessel was immersed in an oil bath and stirred at 95 ° C.
- Comparative Example 2 Synthesis of PDMA A polymerization reaction was performed in the same manner as in Reference Example 4 except that VPA in Reference Example 4 was changed to DMA (manufactured by Wako Pure Chemical Industries, Ltd.) to obtain a polymer (PDMA).
- VPA in Reference Example 4 was changed to DMA (manufactured by Wako Pure Chemical Industries, Ltd.) to obtain a polymer (PDMA).
- Table 1 shows the weight average molecular weight (Mw), number average molecular weight (Mn), and Mw / Mn of the polymers synthesized in Examples 1 to 5 and Comparative Examples 1 and 2.
- Example 6 5 mL of a borate buffer solution (pH 7.1 to 7.3) containing 750 ppm of the copolymer obtained in Example 1 was added to a glass vial, and a commercially available contact lens “2 Week Accuview” (registered trademark) (Johnson End Johnson Co., Ltd.) was immersed and steam sterilized (121 ° C., 30 minutes), and the slipperiness and scuffing durability were evaluated by the above analysis method and evaluation method (2).
- a borate buffer solution pH 7.1 to 7.3
- 750 ppm of the copolymer obtained in Example 1 was added to a glass vial, and a commercially available contact lens “2 Week Accuview” (registered trademark) (Johnson End Johnson Co., Ltd.) was immersed and steam sterilized (121 ° C., 30 minutes), and the slipperiness and scuffing durability were evaluated by the above analysis method and evaluation method (2).
- Example 7 to 10 The slipperiness and the like were evaluated in the same manner as in Example 6 except that the copolymer obtained in Example 1 was changed to the copolymers obtained in Examples 2 to 5 as shown in Table 2.
- Comparative Examples 3-4 The slipperiness and scuffing durability were evaluated in the same manner as in Example 6 except that the copolymer obtained in Example 1 was changed to the copolymer obtained in Comparative Examples 1 and 2 as shown in Table 2. .
- Comparative Example 5 The slipperiness and scuffing durability were evaluated in the same manner as in Example 6 except that the copolymer obtained in Example 1 was changed to polyvinyl pyrrolidone (PVP) (commercial product: PVP-K90) as shown in Table 2. did.
- PVP polyvinyl pyrrolidone
- Comparative Example 6 The slipperiness and the like were evaluated in the same manner as in Example 6 except that the copolymer obtained in Example 1 was changed as shown in Table 2.
- Example 14 10 mg of the copolymer obtained in Example 2 and 0.090 mL of borate buffer solution (pH 7.1 to 7.3) were added to a glass vial and shaken. The resulting solution was colorless and transparent, and the copolymer obtained in Example 2 was completely dissolved.
- Example 15 10 mg of the copolymer obtained in Example 4 and 0.090 mL of borate buffer solution (pH 7.1 to 7.3) were added to a glass vial and shaken. The resulting solution was colorless and transparent, and the copolymer obtained in Example 4 was completely dissolved.
- Comparative Example 8 1.0 mg of the polymer (PVPA) obtained in Comparative Example 1 and 0.90 mL of borate buffer solution (pH 7.1 to 7.3) were added to a glass vial and shaken. Insoluble matter was generated in the obtained solution, and PVPA was not completely dissolved.
- Example 16 An eyeball model was prepared by pouring a 60% by mass acrylamide aqueous solution into a hemispherical metal mold, adding ammonium persulfate to 1% by mass, and allowing to stand at 60 ° C. for 6 hours.
- Example 17 A contact lens was prepared in the same manner as in Example 6 except that a borate buffer containing 200 ppm of the copolymer obtained in Example 4 was used, and the same evaluation as in Example 16 was performed.
- Comparative Example 9 A contact lens was prepared by the same method as in Example 6 except that a borate buffer containing 500 ppm of the polymer obtained in Comparative Example 2 was used, and the same evaluation as in Example 16 was performed.
- Comparative Example 10 A contact lens was prepared by the same method as in Example 6 except that a borate buffer containing 500 ppm of polyvinylpyrrolidone (PVP) (commercial product: PVP-K90) was used, and the same evaluation as in Example 16 was performed. It was.
- PVP polyvinylpyrrolidone
- the solution containing the copolymer according to the present invention improves the lubricity and scuffing durability of medical devices such as ophthalmic lenses (intraocular lenses, contact lenses, spectacle lenses, etc.), endoscopes, catheters, infusion tubes, etc. Can be used.
- ophthalmic lenses intraocular lenses, contact lenses, spectacle lenses, etc.
- endoscopes catheters, infusion tubes, etc.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- General Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Wood Science & Technology (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Materials For Medical Uses (AREA)
- Eyeglasses (AREA)
Abstract
Description
モノマーA:(メタ)アクリロイル基と、エステル構造またはアミド構造とを分子内に有し、前記エステル構造およびアミド構造は、前記(メタ)アクリロイル基の一部を含んで構成されるものではない、モノマー
モノマーB:(メタ)アクリルアミド基を分子内に有し、モノマーAと構造の異なるモノマー
2.基材と、該基材の表面上の少なくとも1部に上記本発明の共重合体を含む医療デバイス。
3.上記本発明の共重合体を含む湿潤剤。
4.上記本発明の湿潤剤を、医療デバイスと接触させることを含む、医療デバイスの湿潤化方法。
5.容器の内に、上記本発明の湿潤剤および医療デバイス基材を入れ、加熱処理する工程を含む、医療デバイスの製造方法。
[式中、R1は水素原子またはメチル基を表す。R2はアルキル基を表す。Xは酸素原子またはNR3を表し、R3は水素原子またはアルキル基を表す。Yは酸素原子またはNR4を表し、R4は水素原子またはアルキル基を表し、また、R4はR2と結合して環構造を形成してもよい。mは1~4の整数を表す。]
(1)ポリマーの分子量測定
島津製作所製 Prominence GPCシステムを用いて測定した。装置構成は以下の通りである。ポンプ:LC-20AD、オートサンプラ:SIL-20AHT、カラムオーブン:CTO-20A、検出器:RID-10A、カラム:東ソー社製GMPWXL(内径7.8mm×30cm、粒子径13μm)。溶出溶媒として、水/メタノール=1/1(0.1N硝酸リチウム添加)を使用し、流速:0.5mL/分、測定時間:30分で測定した。サンプル濃度は0.2質量%とし、サンプル注入量を20μLとした。検量線はAgilent社製PEG/PEO標準サンプル(0.1kD~1258kD)を用いて算出した。
蒸気滅菌した後、コンタクトレンズを包装溶液から引き上げ、人指で5回擦った時の感応評価を下記5段階の評価により行って、0サイクルの易滑性(初期易滑性)とした。この時の易滑性の基準として、市販のコンタクトレンズである「“2ウィークアキュビュー”(登録商標)(J&J社製)」を5段階評価の3、「“アキュビュー”(登録商標)“オアシス”(登録商標)(J&J社製)」を5段階評価の5とした。
4:5と3の中間程度の易滑性がある。
3:中程度の易滑性がある。
2:易滑性がほとんど無い(3と1の中間程度)。
1:易滑性が無い。
カトーテック株式会社製摩擦感テスターKE-SE-STPを用いて測定した。ステージ上によく洗浄した清浄なガラス板を設置し、その上にコンタクトレンズ専用の測定用アダプターを用いてコンタクトレンズ3枚を円周上に等間隔に配置した。コンタクトレンズはホウ酸緩衝液0.1mLを液滴上でガラス面と接触させ、87gの静荷重存在下、2.0mm/秒の速さで測定用アダプターを動かし、表面の動摩擦係数を測定した。
蒸気滅菌した後、コンタクトレンズを包装溶液から引き上げ、幅5mmの短冊状サンプルを切り出し、レンズ外縁部分の厚みを測定、ホウ酸緩衝液に浸漬させて20秒間超音波洗浄した。調製したサンプルはレスカ社製動的接触角計WET-6000を用いて、ホウ酸緩衝液に対する動的接触角の測定を、前進(サンプルをホウ酸緩衝液に漬ける動作)、後退(ホウ酸緩衝液に漬けたサンプル完全に引き上げる動作)を1回とし、これを2回行った時の2回目の動的接触角をそれぞれ比較した(浸漬速度7mm/分)。また、サンプル表面の平滑さや分子配向性を表す指標である、2回目前進値と2回目後退値の差(DCAヒステリシス)を算出した。
日本電子(株)製JNM-EX270核磁共鳴装置を用いて測定した。約5mgの測定対象化合物を約0.6mLの重水素化溶媒(重クロロホルム)に溶解した溶液を測定サンプルとして、1H-NMRを測定した。
参考例1
2-(2-オキソピロリジン-1-イル)エチルアクリレート(VPA)の合成
窒素気流下、冷却管、滴下ロート、塩化カルシウム管を装着した500mL三口フラスコに2-ヒドロキシエチルピロリドン(東京化成工業製、51.68g、400.1mmol)、酢酸エチル(和光純薬製、250mL)、トリエチルアミン(和光純薬製、44.46g、439.4mmol)を入れて10℃まで冷却した混合溶液に、酢酸エチル(和光純薬製、50mL)で希釈した塩化アクリロイル(東京化成工業製、38.03g、420.2mmol)溶液を80分間かけて滴下し、室温に戻してさらに2時間撹拌した。撹拌終了後、ろ過によりトリエチルアミン塩酸塩を取り除き、エバポレーターで溶媒を留去した後、減圧蒸留(146℃、0.05mmHg)により精製することで、無色液体として12.67gの化合物(VPA)を得た。
2-アセトキシエチルアクリレート(AcEA)の合成
窒素気流下、冷却管、滴下ロート、塩化カルシウム管を装着した500mL三口フラスコに、酢酸2-ヒドロキシエチル(東京化成工業製、27.74g、266.4mmol)、酢酸エチル(和光純薬製、260mL)、トリエチルアミン(和光純薬製、29.65g、293.1mmol)を入れて10℃まで冷却した。この混合溶液に、酢酸エチル(和光純薬製、50mL)で希釈した塩化アクリロイル(東京化成工業製、25.31g、279.8mmol)溶液を、80分間かけて滴下した後、室温に戻してさらに2時間撹拌した。撹拌終了後の操作は、参考例1の手順に従って実施した。無色液体として12.41gの目的物(AcEA)を得た。
2-アセトアミドエチルアクリレート(AmEA)の合成
窒素気流下、冷却管、滴下ロート、塩化カルシウム管を装着した500mL三口フラスコに、2-ヒドロキシエチルアセトアミド(東京化成工業製、24.45g、237.1mmol)、酢酸エチル(和光純薬製、250mL)、トリエチルアミン(和光純薬製、27.06g、267.4mmol)を加えた。10℃まで冷却した混合溶液に、酢酸エチル(和光純薬製、50mL)で希釈した塩化アクリロイル(東京化成工業製、23.45g、259.1mmol)溶液を、80分間かけて滴下した後、室温に戻してさらに2時間撹拌した。撹拌終了後の操作は参考例1の手順に従って実施した。黄色液体として23.12gの目的物(AmEA)を得た。
実施例1
コポリマー(VPA/DMA=10/90)の合成
200mL三口フラスコに、参考例1で得た化合物(VPA、1.83g、9.99mmol)、N,N-ジメチルアクリルアミド(DMA、和光純薬製、8.92g、90.0mmol)、重合開始剤として2,2’-アゾビス[2-(2-イミダゾリン-2-イル)プロパン](VA-061、和光純薬製、25.1mg、0.1003mmol)、tert-アミルアルコール(TAA、東京化成工業製、32.25g)を加え、デジタル温度計、三方コックを取り付けたジムロート冷却管、撹拌羽付きシーラーを装着した。続いて、超音波照射下、10mmHgまで減圧して窒素置換するというサイクルを5回繰り返して、混合溶液内の溶存酸素を除去した。反応容器をオイルバスに浸し、70℃で撹拌させながら7時間反応させた後、反応容器をオイルバスから引き上げて、室温まで空冷した。重合反応溶液にエタノール20mLを加えて撹拌し、粘度を下げてから、ヘキサン500mL中へ注いでポリマーを沈殿させた。デカンテーションにより上澄み液を除き、沈殿したポリマーをエタノール20mLに溶解させた。ヘキサン400mLを注いだ後、デカンテーションにより上澄み液を除き、沈殿したポリマーを真空乾燥機中で40℃にて終夜加熱乾燥させた。白色粉末として9.65gのコポリマー(VPA/DMA=10/90)を得た(収率90%)。
コポリマー(VPA/DMA=30/70)の合成
200mL三口フラスコに参考例1で得たVPA(2.78g、15.2mmol)、DMA(和光純薬製、3.56g、35.9mmol)、重合開始剤として2,2’-アゾビス(2,4-ジメチルバレロニトリル)(ADVN、和光純薬製、25.1mg、0.101mmol)、TAA(東京化成工業製、11.77g)を加え、デジタル温度計、三方コックを取り付けたジムロート冷却管、撹拌羽付きシーラーを装着した。実施例1の手順に従って、溶存酸素の除去操作、加熱撹拌、再沈殿、加熱乾燥を行い、白色粉末として4.80gのコポリマー(VPA/DMA=30/70)を得た(収率75%)。
コポリマー(VPA/DMA=50/50)の合成
200mL三口フラスコに参考例1で得たVPA(4.54g、24.8mmol)、DMA(和光純薬製、2.46g、24.8mmol)、重合開始剤として2,2’-アゾビス[2-(2-イミダゾリン-2-イル)プロパン](VA-061、和光純薬製、13.8mg、0.0551mmol)、TAA(東京化成工業製、21.13g)を加え、デジタル温度計、三方コックを取り付けたジムロート冷却管、撹拌羽付きシーラーを装着した。実施例1の手順に従って、溶存酸素の除去操作、加熱撹拌、再沈殿、加熱乾燥を行い、白色粉末として4.80gのコポリマー(VPA/DMA=50/50)を得た(収率68%)。
コポリマー(AcEA/DMA=10/90)の合成
200mL四口フラスコに、TAA(東京化成工業製、20.15g)を加え、滴下漏斗、デジタル温度計、三方コックを取り付けたジムロート冷却管、撹拌羽付きシーラーを装着した。続いて、窒素を10分間バブリングさせて、溶媒内の溶存酸素を除去した。反応容器をオイルバスに浸し、95℃で撹拌した。
コポリマー(AmEA/DMA=10/90)の合成
200mL四口フラスコに、TAA(東京化成工業製、20.15g)を加え、滴下漏斗、デジタル温度計、三方コックを取り付けたジムロート冷却管、撹拌羽付きシーラーを装着した。続いて、窒素を10分間バブリングさせて、溶媒内の溶存酸素を除去した。反応容器をオイルバスに浸し、95℃で撹拌した。
ポリVPA(PVPA)の合成
200mL三口フラスコに、参考例1で得たVPA(4.58g、25.0mmol)、重合開始剤としてVA-061(和光純薬製、6.3mg、0.0252mmol)、TAA(東京化成工業製、10.68g)を加え、デジタル温度計、三方コックを取り付けたジムロート冷却管、撹拌羽付きシーラーを装着した。続いて、超音波照射下、10mmHgまで減圧して窒素置換するというサイクルを5回繰り返して、混合溶液内の溶存酸素を除去した。反応容器をオイルバスに浸し、70℃で撹拌しながら7時間反応させた後、反応容器をオイルバスから引き上げて室温まで空冷した。重合反応溶液にエタノール20mLを加えて撹拌し、粘度を下げてから、ヘキサン500mL中へ注いでポリマーを沈殿させた。デカンテーションにより上澄み液を除き、沈殿したポリマーをエタノール20mLに溶解させた。ヘキサン400mLを注いだ後、デカンテーションにより上澄み液を除き、沈殿したポリマーを真空乾燥機中で40℃にて終夜加熱乾燥させた。黄色粘調固体として3.51gのポリマー(PVPA)を得た。
PDMAの合成
参考例4のVPAをDMA(和光純薬製)に変える以外は参考例4と同様にして重合反応を行い、ポリマー(PDMA)を得た。
実施例6
実施例1で得た共重合体を750ppm含有するホウ酸緩衝溶液(pH7.1~7.3)5mLをガラスバイアル瓶に加え、市販のコンタクトレンズ“2ウィーク アキュビュー”(登録商標)(ジョンソン・エンド・ジョンソン社製)を浸漬させ、蒸気滅菌(121℃、30分)した後、上記分析方法および評価方法(2)にて易滑性および擦り洗い耐久性を評価した。
実施例1で得た共重合体を表2の通りに実施例2~5で得た共重合体にそれぞれ変える以外は実施例6と同様にして、易滑性等を評価した。
実施例1で得た共重合体を表2の通りに比較例1~2で得た共重合体にそれぞれ変える以外は実施例6と同様にして、易滑性および擦り洗い耐久性を評価した。
実施例1で得た共重合体を表2の通りにポリビニルピロリドン(PVP)(市販品:PVP-K90)に変える以外は実施例6と同様にして、易滑性および擦り洗い耐久性を評価した。
実施例1で得た共重合体を表2の通りに変える以外は実施例6と同様にして、易滑性等を評価した。
実施例11~13
実施例6~8で表面コーティングしたコンタクトレンズをそれぞれ用い、上記分析方法および評価方法(3)および(4)にて、動摩擦係数とDCAヒステリシスを測定した。
比較対象として、市販のコンタクトレンズ“ワンデー アキュビュー”(登録商標)“モイスト”(登録商標)」(ジョンソン・エンド・ジョンソン社製)を用い、実施例11と同様にして動摩擦係数とDCAヒステリシスを測定した。実施例11~13および比較例7の動摩擦係数(MIU)、動的接触角(DCA)およびDCAヒステリシス測定結果を、表3に示す。
実施例14
実施例2で得た共重合体10mgと、ホウ酸緩衝溶液(pH7.1~7.3)0.090mLをガラスバイアル瓶に加えて震蕩した。得られた溶液は無色透明であり、実施例2で得た共重合体は完全に溶解していた。
実施例4で得た共重合体10mgと、ホウ酸緩衝溶液(pH7.1~7.3)0.090mLをガラスバイアル瓶に加えて震蕩した。得られた溶液は無色透明であり、実施例4で得た共重合体は完全に溶解していた。
比較例1で得た重合体(PVPA)1.0mgと、ホウ酸緩衝溶液(pH7.1~7.3)0.90mLをガラスバイアル瓶に加えて震蕩した。得られた溶液には、不溶物が生じており、PVPAは完全には溶解しなかった。
実施例16
60質量%アクリルアミド水溶液を半球状の金属モールドに流し込み、1質量%になるよう過硫酸アンモニウムを添加し、60℃で6時間静置することで、眼球モデルを作製した。
4:モデル上で良好に動き、ある程度の時間湿潤状態を維持し、取り外す際に抵抗が少ない。
3:モデル上で動きがあり、短時間湿潤状態を維持し、取り外す際に若干抵抗がある。
2:モデル上で動きが少なく、非常に短時間湿潤状態を維持し、取り外す際にかなり抵抗がある。
1:モデル上で動かず、湿潤状体を維持できず、取り外しが困難。
実施例4で得られた共重合体を200ppm含有するホウ酸緩衝液を用いた以外は、実施例6と同様の方法によりコンタクトレンズを調製し、実施例16と同様の評価を行った。
比較例2で得られたポリマーを500ppm含有するホウ酸緩衝液を用いた以外は、実施例6と同様の方法によりコンタクトレンズを調製し、実施例16と同様の評価を行った。
ポリビニルピロリドン(PVP)(市販品:PVP-K90)を500ppm含有するホウ酸緩衝液を用いた以外は、実施例6と同様の方法によりコンタクトレンズを調製し、実施例16と同様の評価を行った。
Claims (20)
- 下記モノマーAと下記モノマーBとを構成単位とし、水可溶性である共重合体。
モノマーA:(メタ)アクリロイル基と、エステル構造またはアミド構造とを分子内に有し、前記エステル構造およびアミド構造は、前記(メタ)アクリロイル基の一部を含んで構成されるものではない、モノマー
モノマーB:(メタ)アクリルアミド基を分子内に有し、モノマーAと構造の異なるモノマー - 前記モノマーAにおいて、前記(メタ)アクリロイル基が、ヘテロ原子を有する二価の炭化水素基を介して前記エステル構造またはアミド構造と結合している、請求項1記載の共重合体。
- 前記モノマーAの含有率が5~50モル%で、前記モノマーBの含有率が50~95モル%である、請求項1~5のいずれか一項記載の共重合体。
- 基材と、該基材の表面上の少なくとも1部に請求項1~6のいずれか1項に記載の共重合体を含む医療デバイス。
- 眼用レンズである、請求項7記載の医療デバイス。
- 前記眼用レンズがコンタクトレンズである、請求項8記載の医療デバイス。
- 請求項1~6のいずれか一項記載の共重合体を含む湿潤剤。
- 水溶液の形態にある請求項10記載の湿潤剤。
- 外部湿潤剤である請求項11記載の湿潤剤。
- 医療デバイス用である請求項10~12のいずれか1項に記載の湿潤剤。
- 前記医療デバイスが眼用レンズである、請求項13記載の湿潤剤。
- 前記眼用レンズがコンタクトレンズである、請求項14記載の湿潤剤。
- 請求項10~12のいずれか1項に記載の湿潤剤を、医療デバイスと接触させることを含む、医療デバイスの湿潤化方法。
- 接触を加熱下で行う請求項16記載の方法。
- 前記医療デバイスが眼用レンズである、請求項16又は17記載の方法。
- 前記眼用レンズがコンタクトレンズである、請求項18記載の方法。
- 容器の内に、請求項10~15のいずれか一項記載の湿潤剤および医療デバイス基材とを入れ、加熱処理する工程を含む、医療デバイスの製造方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/085,860 US20190099511A1 (en) | 2016-03-31 | 2017-03-17 | Copolymer, wetting agent, medical device, and method for producing same |
EP17774417.4A EP3438144B1 (en) | 2016-03-31 | 2017-03-17 | Copolymer, wetting agent, medical device, and method for producing same |
JP2017515866A JP6939548B2 (ja) | 2016-03-31 | 2017-03-17 | 共重合体、湿潤剤、医療デバイスおよびその製造方法 |
US17/035,860 US11591426B2 (en) | 2016-03-31 | 2020-09-29 | Copolymer, wetting agent, medical device, and method for producing same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016-071298 | 2016-03-31 | ||
JP2016071298 | 2016-03-31 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/085,860 A-371-Of-International US20190099511A1 (en) | 2016-03-31 | 2017-03-17 | Copolymer, wetting agent, medical device, and method for producing same |
US17/035,860 Division US11591426B2 (en) | 2016-03-31 | 2020-09-29 | Copolymer, wetting agent, medical device, and method for producing same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017169873A1 true WO2017169873A1 (ja) | 2017-10-05 |
Family
ID=59964470
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/010824 WO2017169873A1 (ja) | 2016-03-31 | 2017-03-17 | 共重合体、湿潤剤、医療デバイスおよびその製造方法 |
Country Status (4)
Country | Link |
---|---|
US (2) | US20190099511A1 (ja) |
EP (1) | EP3438144B1 (ja) |
JP (1) | JP6939548B2 (ja) |
WO (1) | WO2017169873A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020235275A1 (ja) * | 2019-05-20 | 2020-11-26 | 東レ株式会社 | 医療デバイスの製造方法 |
EP3859431A4 (en) * | 2018-11-09 | 2022-06-29 | Toray Industries, Inc. | Medical device and method for manufacturing same |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210127952A1 (en) * | 2017-08-01 | 2021-05-06 | Seed Co., Ltd. | Endoscope hood |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS522431A (en) * | 1975-06-23 | 1977-01-10 | Fuji Photo Film Co Ltd | Material for color diffusion transfer photography |
JPS59130853A (ja) * | 1982-12-29 | 1984-07-27 | ポラロイド・コ−ポレ−シヨン | 拡散転写写真フイルム単位 |
JPS59171848A (ja) * | 1983-03-18 | 1984-09-28 | Fuji Photo Film Co Ltd | 電気泳動用媒体 |
JPH01111094A (ja) * | 1987-10-21 | 1989-04-27 | Kao Corp | 製紙用サイズ剤組成物 |
JPH0222555A (ja) * | 1988-05-02 | 1990-01-25 | Eastman Kodak Co | 電気泳動ゲル媒体用キット |
JPH1072427A (ja) * | 1989-12-20 | 1998-03-17 | Ceskoslovenska Akad Ved | N,o−ジメタクリロイルヒドロキシルアミン |
JP2002143668A (ja) * | 2000-08-22 | 2002-05-21 | E I Du Pont De Nemours & Co | グラフトコポリマー顔料分散剤 |
JP2004045626A (ja) * | 2002-07-10 | 2004-02-12 | Fuji Photo Film Co Ltd | 画像記録材料 |
JP2012501311A (ja) * | 2008-09-02 | 2012-01-19 | ビーエーエスエフ ソシエタス・ヨーロピア | レオロジー改良剤として有用なコポリマならびにホームケアおよびパーソナルケア組成物 |
CN103788290A (zh) * | 2012-10-29 | 2014-05-14 | 中国石油化工股份有限公司 | 一种丙烯酰胺系共聚物及其制备方法和应用 |
CN103788289A (zh) * | 2012-10-29 | 2014-05-14 | 中国石油化工股份有限公司 | 一种丙烯酰胺系共聚物及其制备方法和应用 |
CN103788292A (zh) * | 2012-10-29 | 2014-05-14 | 中国石油化工股份有限公司 | 一种丙烯酰胺系共聚物及其制备方法和应用 |
JP2014114430A (ja) * | 2012-03-13 | 2014-06-26 | Central Glass Co Ltd | 防曇膜形成材料、防曇膜形成用塗布液、防曇性物品、及びそれらの製法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS522431B2 (ja) | 1972-06-27 | 1977-01-21 | ||
EP0306246A3 (en) | 1987-08-31 | 1990-03-07 | Konica Corporation | Silver halide photographic material |
JPS6472427A (en) | 1987-09-14 | 1989-03-17 | Toshiba Corp | Manufacture and device of superconducting thin film |
WO2002024793A1 (en) * | 2000-09-19 | 2002-03-28 | Bausch & Lomb Incorporated | Method for applying polymeric lens coating |
BRPI0607430B8 (pt) | 2005-02-14 | 2021-06-22 | Johnson & Johnson Vision Care | dispositivo oftálmico confortável e métodos de sua produção |
CA2683513A1 (en) * | 2007-05-18 | 2008-11-27 | Basf Se | Aqueous dispersions of (meth)acrylic esters of polymers comprising n-hydroxyalkylated lactam units and use of (meth)acrylic esters of polymers comprising n-hydroxyalkylated lactamunits |
US20090173045A1 (en) | 2008-01-09 | 2009-07-09 | Yu-Chin Lai | Packaging Solutions |
WO2011063208A1 (en) * | 2009-11-20 | 2011-05-26 | Isp Investments Inc. | Alkyl lactam ester polymers, and uses thereof |
JP2011245053A (ja) * | 2010-05-27 | 2011-12-08 | Nanyang Technological Univ | 眼用及び医療用の重合性組成物及びそれを重合して得られる抗菌性組成物 |
-
2017
- 2017-03-17 US US16/085,860 patent/US20190099511A1/en not_active Abandoned
- 2017-03-17 EP EP17774417.4A patent/EP3438144B1/en active Active
- 2017-03-17 JP JP2017515866A patent/JP6939548B2/ja active Active
- 2017-03-17 WO PCT/JP2017/010824 patent/WO2017169873A1/ja active Application Filing
-
2020
- 2020-09-29 US US17/035,860 patent/US11591426B2/en active Active
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS522431A (en) * | 1975-06-23 | 1977-01-10 | Fuji Photo Film Co Ltd | Material for color diffusion transfer photography |
JPS59130853A (ja) * | 1982-12-29 | 1984-07-27 | ポラロイド・コ−ポレ−シヨン | 拡散転写写真フイルム単位 |
JPS59171848A (ja) * | 1983-03-18 | 1984-09-28 | Fuji Photo Film Co Ltd | 電気泳動用媒体 |
JPH01111094A (ja) * | 1987-10-21 | 1989-04-27 | Kao Corp | 製紙用サイズ剤組成物 |
JPH0222555A (ja) * | 1988-05-02 | 1990-01-25 | Eastman Kodak Co | 電気泳動ゲル媒体用キット |
JPH1072427A (ja) * | 1989-12-20 | 1998-03-17 | Ceskoslovenska Akad Ved | N,o−ジメタクリロイルヒドロキシルアミン |
JP2002143668A (ja) * | 2000-08-22 | 2002-05-21 | E I Du Pont De Nemours & Co | グラフトコポリマー顔料分散剤 |
JP2004045626A (ja) * | 2002-07-10 | 2004-02-12 | Fuji Photo Film Co Ltd | 画像記録材料 |
JP2012501311A (ja) * | 2008-09-02 | 2012-01-19 | ビーエーエスエフ ソシエタス・ヨーロピア | レオロジー改良剤として有用なコポリマならびにホームケアおよびパーソナルケア組成物 |
JP2014114430A (ja) * | 2012-03-13 | 2014-06-26 | Central Glass Co Ltd | 防曇膜形成材料、防曇膜形成用塗布液、防曇性物品、及びそれらの製法 |
CN103788290A (zh) * | 2012-10-29 | 2014-05-14 | 中国石油化工股份有限公司 | 一种丙烯酰胺系共聚物及其制备方法和应用 |
CN103788289A (zh) * | 2012-10-29 | 2014-05-14 | 中国石油化工股份有限公司 | 一种丙烯酰胺系共聚物及其制备方法和应用 |
CN103788292A (zh) * | 2012-10-29 | 2014-05-14 | 中国石油化工股份有限公司 | 一种丙烯酰胺系共聚物及其制备方法和应用 |
Non-Patent Citations (1)
Title |
---|
See also references of EP3438144A4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3859431A4 (en) * | 2018-11-09 | 2022-06-29 | Toray Industries, Inc. | Medical device and method for manufacturing same |
TWI799652B (zh) * | 2018-11-09 | 2023-04-21 | 日商東麗股份有限公司 | 醫療裝置及其製造方法 |
WO2020235275A1 (ja) * | 2019-05-20 | 2020-11-26 | 東レ株式会社 | 医療デバイスの製造方法 |
CN113785236A (zh) * | 2019-05-20 | 2021-12-10 | 东丽株式会社 | 医疗设备的制造方法 |
TWI833012B (zh) * | 2019-05-20 | 2024-02-21 | 日商東麗股份有限公司 | 醫療裝置之製造方法 |
Also Published As
Publication number | Publication date |
---|---|
US20190099511A1 (en) | 2019-04-04 |
JP6939548B2 (ja) | 2021-09-22 |
US11591426B2 (en) | 2023-02-28 |
JPWO2017169873A1 (ja) | 2019-02-07 |
US20210015960A1 (en) | 2021-01-21 |
EP3438144B1 (en) | 2021-06-30 |
EP3438144A4 (en) | 2019-11-06 |
EP3438144A1 (en) | 2019-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11591426B2 (en) | Copolymer, wetting agent, medical device, and method for producing same | |
JP6807011B2 (ja) | 表面にホスホリルコリン基含有親水性ポリマーを有するコンタクトレンズ | |
JP2532406B2 (ja) | 耐衝撃性の優れた酸素透過性ハ−ドコンタクトレンズ用材料 | |
JP5707843B2 (ja) | コンタクトレンズ用ケア製剤及びパッケージング溶液 | |
RU2682111C1 (ru) | Контактная линза с модифицированной поверхностью и способ ее получения | |
WO2013128633A1 (ja) | コンタクトレンズ用ケア製剤及びパッケージング溶液 | |
JP2007014637A (ja) | 環状シロキサン化合物を重合して得られる眼科用レンズ、細胞または臓器の培養基材、生体物容器、透明ゲルおよびその製造方法 | |
JP5609525B2 (ja) | コンタクトレンズ用ケア製剤及びパッケージング溶液 | |
TWI609957B (zh) | 用以處理隱形眼鏡之溶液及隱形眼鏡的包裝系統 | |
JP6908878B2 (ja) | 医療用高分子、医療用高分子溶液および医療デバイスの製造方法 | |
CN109814276A (zh) | 眼用镜片及其制造方法 | |
JP6944124B2 (ja) | 眼科用剤 | |
JP7415306B2 (ja) | 眼用レンズ用組成物 | |
JP3974673B2 (ja) | 含水性ソフトコンタクトレンズ | |
WO2023199855A1 (ja) | 共重合体、医療用組成物及び被覆医療デバイス並びにそれらの製造方法 | |
JP6879446B2 (ja) | 共重合体、医療デバイスおよびその製造方法、医療デバイス用湿潤剤および化合物 | |
TWI827762B (zh) | 醫療裝置 | |
JPWO2016148146A1 (ja) | メディカルデバイス、メディカルデバイスの製造方法及びメディカルデバイス用表面処理液 | |
JPH0682178B2 (ja) | ソフトコンタクトレンズ用材料 | |
WO2023190365A1 (ja) | 共重合体及びコンタクトレンズ用処理液 | |
WO2023276858A1 (ja) | ソフトコンタクトレンズ用溶液 | |
JP2024042676A (ja) | コンタクトレンズ用モノマー組成物、コンタクトレンズ用重合体、並びにコンタクトレンズ | |
WO2022118701A1 (ja) | 眼科デバイス用表面処理剤 | |
WO2024143214A1 (ja) | 硬化性組成物、成形体、シリコーンハイドロゲル及びその製造方法 | |
WO2022179477A1 (zh) | 隐形眼镜材料及隐形眼镜镜片 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2017515866 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017774417 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017774417 Country of ref document: EP Effective date: 20181031 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17774417 Country of ref document: EP Kind code of ref document: A1 |